📇 Rhumatologue ·
Chargement de la fiche…
Chargement de la fiche…
MonRhumato.fr utilise des cookies pour mesurer l'audience (statistiques) et améliorer le site. Aucune donnée de santé identifiable n'est jamais collectée. Politique de confidentialité.
Votre choix est conservé 13 mois (durée max CNIL). Vous pouvez le modifier à tout moment via Préférences cookies.
1 raison identifiée
Auteur de référence en rhumatologie
22 articles scientifiques publiés — un praticien à la pointe de la recherche
✨ Génération du profil synthétique IA en cours…
Articles déposés en accès libre sur l'archive ouverte des universités françaises (HAL) — gage d'activité de recherche en France.
Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.
Risk factors for hydroxychloroquine retinopathy in systemic lupus erythematosus: a case–control study with hydroxychloroquine blood-level analysis
2020ArticleRheumatology
Source : HAL — archive ouverte CCSD/CNRS (couvre articles, chapitres EMC, communications congrès, thèses).
Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).
Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).
Arthritis and rheumatism · 2003
AbstractObjectiveTo analyze specific clinical findings, underlying disorders, treatments, outcomes, and prognostic factors for reactive hemophagocytic syndrome (RHS) in systemic disease.MethodsData were collected using standardized forms as part of a French national survey. Adult cases without an underlying malignancy, diagnosed on bone marrow or lymph node biopsy, were included.ResultsTwenty‐six cases (7 men, 19 women, mean age 47.4 ± 17.7 years) were studied. Systemic diseases included systemic lupus erythematosus (n = 14), rheumatoid arthritis (n = 2), adult onset systemic Still's disease (n = 4), polyarteritis nodosa (n = 2), mixed connective tissue disease (n = 1), pulmonary sarcoidosis (n = 1), systemic sclerosis (n = 1), and Sjögren's syndrome (n = 1). RHS occurred in 2 distinct clinical settings in the course of systemic disease. RHS was associated with an active infection in 15 patients (bacterial infections, 10 cases; viral, 3 cases; tuberculosis, 1 case; and aspergillosis, 1 case) and with the onset of a systemic disease alone in 9 cases. Isolated RHS occurred in 2 cases. The overall mortality rate was 38.5%. Two factors were associated with mortality: corticosteroid treatment at the time of RHS diagnosis, and thrombocytopenia (odds ratio = 28, 95% confidence interval = 13.3−238.9).ConclusionsWhen RHS occurs in the course of an active systemic disease (situation only reported in cases of systemic lupus or adult Still's disease), immunosuppressive therapy should be used. In contrast, when RHS is present concomitantly with an active infection, immunosuppressive therapy needs to be lowered and antibiotic therapy should be instituted.
Arthritis and rheumatism · 2007
AbstractObjectiveTo describe characteristics and outcomes of vasculitides associated with malignancies.MethodsThe requirement for inclusion in this retrospective, 10‐year study was development of vasculitis in patients with a progressing malignancy. Malignancies secondary to immunosuppressants used to treat vasculitis were excluded. The main characteristics of vasculitides were analyzed and compared according to the type of malignancy.ResultsSixty patients were included (male/female sex ratio 2.53, mean age 62.4 years). Mean followup duration was 45.2 months. Vasculitides were cutaneous leukocytoclastic (45%), polyarteritis nodosa (36.7%), Wegener's granulomatosis (6.7%), microscopic polyangiitis (5%), and Henoch‐Schönlein purpura (5%). Malignancies were distributed as follows: hematologic in 63.1%, myelodysplastic syndrome (MDS) in 32.3%, lymphoid in 29.2%, and solid tumor in 36.9%. Vasculitides were diagnosed concurrently with malignancy in 38% of the cases. Manifestations of vasculitides were fever (41.7%), cutaneous involvement (78.3%), arthralgias (46.7%), peripheral neuropathy (31.7%), renal involvement (23.3%; 11.7% glomerulonephritis, 11.7% microaneurysms, 6.7% renal insufficiency), and antineutrophil cytoplasmic antibody (20.4%). Vasculitis treatments were corticosteroids (78.3%) and immunosuppressant(s) (41.7%). Vasculitis was cured in 65% of patients, but 58.3% died, with 1 death secondary to vasculitis. Independent of subtype, patients with vasculitides associated with MDS more frequently had renal manifestations (P = 0.02) and steroid dependence (P = 0.04) and achieved complete remission less often (P = 0.04) than patients with vasculitides associated with other malignancies. Patients with vasculitides associated with a solid tumor more frequently had peripheral neurologic involvement (P = 0.05). Patients with vasculitides associated with lymphoid malignancy had less frequent arthralgias (P = 0.01) and renal involvement (P = 0.02).ConclusionVasculitides occurring during malignancies present distinctive features according to the vasculitis subtype and nature of the malignancy.
Gastroenterology · 2002
Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).
Journal of the American Academy of Dermatology · 2020 · Letter
Monseau G, Landon-Cardinal O, Stenzel W, Schoindre Y, et al.
Arthritis care & research · 2013 · Journal Article
Droz N, Gilardin L, Cacoub P, Berenbaum F, et al.
La Revue de medecine interne · 2011 · Case Reports
Charles P, Ackermann F, Brousse C, Piette AM, et al.
Annales de dermatologie et de venereologie · 2009 · English Abstract
Blétry O, Sene T, Kahn JE, Ackermann F, et al.
Arthritis and rheumatism · 2007 · Journal Article
Fain O, Hamidou M, Cacoub P, Godeau B, et al.
Presse medicale (Paris, France : 1983) · 2007 · Case Reports
Girszyn N, Leport J, Arnaud L, Kahn JE, et al.
Archives of dermatology · 2006 · Case Reports
Terrier B, Piette AM, Kerob D, Cordoliani F, et al.
Autoimmunity · 2006 · Journal Article
Montano-Loza A, Czaja AJ, Carpenter HA, Piette A, et al.
La Revue de medecine interne · 2003 · Case Reports
Aouba A, Lidove O, Gepner P, Brousse C, et al.
Gastroenterology · 2002 · Case Reports
Izzedine H, Simon J, Piette AM, Lucsko M, et al.
European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2002 · Case Reports
Larroche C, Scieux C, Honderlick P, Piette AM, et al.
Revue du rhumatisme et des maladies osteo-articulaires · 1992 · Case Reports
Gepner P, Piette AM, Patrat JF, Graveleau P, et al.
Presse medicale (Paris, France : 1983) · 1992 · Case Reports
Piette AM, Legoux B, Gepner P, Chapman A
Dermatologica · 1989 · Case Reports
Francès C, Tribout B, Boisnic S, Drouet L, et al.
Revue du rhumatisme et des maladies osteo-articulaires · 1981 · Case Reports
Piette AM, Prier A, Camus JP, di Crescenzo MC
La Revue de medecine interne · 2000 · Comparative Study
Hachulla E, Piette AM, Hatron PY, Blétry O
Annales de medecine interne · 1996 · Journal Article
Piette JC, Piette AM
Presse medicale (Paris, France : 1983) · 1994 · English Abstract
Piette AM, Mourad JJ, Karmochkine M, Didon D, et al.
Arthritis and rheumatism · 2003 · Journal Article
Dhote R, Simon J, Papo T, Detournay B, et al.
La Revue de medecine interne · 1999 · Case Reports
Piette AM, Ramanoelina J, Gepner P, Larroche C, et al.
La semaine des hopitaux : organe fonde par l'Association d'enseignement medical des hopitaux de Paris · 1982 · English Abstract
Piette AM, Dorra M, Betourne C, Levy R, et al.
European journal of internal medicine · 2006 · Journal Article
Arnaud L, Kahn JE, Girszyn N, Piette AM, et al.